EBMT 2026 | Identifying the broad spectrum of neurological complications following transplantation and CAR-T
Roser Velasco, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, briefly discusses the spectrum of neurological complications associated with allogeneic transplantation, CAR T-cell therapy, and bispecific antibodies, highlighting that these complications are multifactorial and can differ across therapies yet often share common characteristics. Dr Velasco emphasizes the importance of careful clinical observation to identify new symptoms, whether focal or generalized, and to monitor their progression and severity. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, yeah, it’s true that the spectrum is being changed because CAR-T is a new therapy, so we are becoming aware of these complications, but also in allogeneic stem cell transplantation, new complications related to prior treatments or longer survivals of these patients are occurring. So yeah, we can say that neurologic complications are a broad spectrum associated with multifactorial causes that are not the same among the three types of therapies but in most cases they share that the vulnerability of the patient, the treatment that they have received, the timing can differ, but they can share some particularities...
Well, yeah, it’s true that the spectrum is being changed because CAR-T is a new therapy, so we are becoming aware of these complications, but also in allogeneic stem cell transplantation, new complications related to prior treatments or longer survivals of these patients are occurring. So yeah, we can say that neurologic complications are a broad spectrum associated with multifactorial causes that are not the same among the three types of therapies but in most cases they share that the vulnerability of the patient, the treatment that they have received, the timing can differ, but they can share some particularities.
In neurology, it’s very important to be careful in seeing the patient to catch which are the new symptoms, if they are focal or they are generalized. And it’s very important the progression of these symptoms and the severity. So, yeah, I will say that, as always, the good clinician should be aware of what’s happening new to the patient. Sometimes these symptoms are subjective or even subtle, and we have to be very wise to see if something is really happening at the moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
